Hard To Treat Diseases (HTDS) Earnings Comparisons and Preliminary Q4 Results

SHENZHEN, China , Jan. 4 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS; www.htdsmedical.com) announced that it is offering an earnings guidance range for 2009, citing the volatility of its quarterly earnings results.

Terry Yuan , HTDS President, said, "In the view of recent variation of our earnings and sales results, we feel that to present a better quality of disclosure we are obliged to offer earnings guidance to our shareholders for 2009. We recognize that the bulky nature of our sales and our research results may be distracting to some, and we offer this guidance in order for the investors to forget short-term, quarter-to-quarter variations, and start focusing on the long-term success. We hope this will be a one-time event, as we would rather have the company focused on its long-term development, which, as many can see, is unusually promising.

The company expects Q4 2009 gross revenue to come in at around $3,000,000 USD , with gross profits of about $700,000 USD . This is dramatically better than 2009 Q3 ( $481,949 and $541 respectively) and significantly better than 2008 Q4 results with revenues of $931,970 USD and profit of $258,110 USD . HTDS anticipates its Total Gross Revenues to reach in the range of 5,250,000 $ USD for the fiscal year 2009. As shareholders can see, compared to 2008, with the total revenues of $4,277,639 USD , 2009 revenue results represent a substantial improvement," said Mr. Yuan, and continued "however, we ask our shareholders to recognize that our individual sales are relatively large in relation to our total revenues and can only be booked for accounting purposes under certain circumstances, regardless of how certain they are to occur. This makes for swings in results that can only be balanced over several periods of a year. We have established a relatively wide range for our 2009 guidance to cover various potential outcomes."

Mr. Yuan said further "Despite the soft world economy and the fact that many of the developing countries we market our products in are under economic strain, we still expect 2010 results to show rapid growth. We expect to grow due fact that the vaccines are a highly dynamic medical market at the present moment and we expect this trend to continue. Over four million children die each year needlessly, as they could have been saved by a simple and cheap vaccination, and that's where we come in." Mr. Yuan said. "Our focus, as always, is on ensuring we have sufficient products to meet our customers' needs, both today and in the future. We will continue to invest in worldwide marketing, but it is also important to understand the major significance of our medical research results."

HTDS has two subsidiaries, Slavica Bio Chem Co and China Mellow Hope Inc. www.mellowhope.com. Slavica's primary focus involves the enhancement and modification of existing approved drugs such as "Virazole" for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatitis C. Mellow Hope is China -based and is the biggest exporter of Biological Vaccines in China . It has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestatin.

Lastly, with the sale of our MindUp project this will allow us and afford us the opportunity to develop our stem cell bank and rejuvenate medical procedures project(s) which we see as a great vehicle to propel HTDS to new heights and add value to our company and our shareholders.

In other company news, (see filings Pink Sheets) the management had received information from its Transfer Agent (TA) Heritage Trust Company that it had identified the source of the security stock's "chill", which has now been resolved. As an important result for the investors, the DTC lifted the trading restrictions on the HTDS security which should follow Pink Sheets removal of skull and bones rank as well as this matter is now dealt with and resolved.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contactwww.minamargroup.com/helpdesk

SOURCE Hard to Treat Diseases